Charles River Laboratories Intl. Inc (NYSE:CRL) Shares Bought by Nelson Van Denburg & Campbell Wealth Management Group LLC

Share on StockTwits

Nelson Van Denburg & Campbell Wealth Management Group LLC raised its position in Charles River Laboratories Intl. Inc (NYSE:CRL) by 22.0% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,270 shares of the medical research company’s stock after buying an additional 410 shares during the period. Nelson Van Denburg & Campbell Wealth Management Group LLC’s holdings in Charles River Laboratories Intl. were worth $300,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Flagship Harbor Advisors LLC increased its holdings in Charles River Laboratories Intl. by 132.1% in the second quarter. Flagship Harbor Advisors LLC now owns 318 shares of the medical research company’s stock valued at $45,000 after buying an additional 181 shares in the last quarter. Steward Partners Investment Advisory LLC purchased a new position in Charles River Laboratories Intl. in the second quarter valued at $69,000. Point72 Asset Management L.P. purchased a new position in Charles River Laboratories Intl. in the second quarter valued at $71,000. Machina Capital S.A.S. purchased a new position in Charles River Laboratories Intl. in the second quarter valued at $72,000. Finally, Hilton Capital Management LLC purchased a new position in Charles River Laboratories Intl. in the first quarter valued at $118,000. 94.31% of the stock is owned by institutional investors.

A number of research analysts have weighed in on CRL shares. Zacks Investment Research cut shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a report on Monday, September 30th. ValuEngine cut shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Credit Suisse Group set a $138.00 price objective on shares of Charles River Laboratories Intl. and gave the company a “hold” rating in a report on Friday, September 13th. Finally, SunTrust Banks lifted their price objective on shares of Charles River Laboratories Intl. from $156.00 to $162.00 and gave the company a “buy” rating in a report on Monday, September 16th. Six analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $150.50.

CRL stock opened at $130.81 on Friday. The stock has a market capitalization of $6.32 billion, a P/E ratio of 21.69, a P/E/G ratio of 1.65 and a beta of 1.09. The firm has a 50-day simple moving average of $131.91 and a 200-day simple moving average of $135.04. The company has a quick ratio of 1.38, a current ratio of 1.59 and a debt-to-equity ratio of 1.47. Charles River Laboratories Intl. Inc has a 52 week low of $103.00 and a 52 week high of $149.07.

Charles River Laboratories Intl. (NYSE:CRL) last released its earnings results on Wednesday, July 31st. The medical research company reported $1.63 EPS for the quarter, topping analysts’ consensus estimates of $1.55 by $0.08. The business had revenue of $657.60 million during the quarter, compared to analysts’ expectations of $662.61 million. Charles River Laboratories Intl. had a net margin of 8.94% and a return on equity of 22.01%. The company’s quarterly revenue was up 12.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.62 earnings per share. On average, analysts expect that Charles River Laboratories Intl. Inc will post 6.52 earnings per share for the current year.

In other news, insider David Ross Smith sold 1,249 shares of the business’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $130.36, for a total transaction of $162,819.64. Following the completion of the sale, the insider now owns 19,327 shares of the company’s stock, valued at $2,519,467.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.80% of the stock is owned by insiders.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Featured Article: What is the float in trading stocks?

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Jefferies Financial Group Brokers Lower Earnings Estimates for Millendo Therapeutics Inc
Jefferies Financial Group Brokers Lower Earnings Estimates for Millendo Therapeutics Inc
FY2019 EPS Estimates for Nice Ltd Boosted by Analyst
FY2019 EPS Estimates for Nice Ltd Boosted by Analyst
Quanta Services Inc  Expected to Post FY2019 Earnings of $2.97 Per Share
Quanta Services Inc Expected to Post FY2019 Earnings of $2.97 Per Share
Deutsche Bank Reiterates “CHF 350” Price Target for Zurich Insurance Group
Deutsche Bank Reiterates “CHF 350” Price Target for Zurich Insurance Group
Desjardins Analysts Increase Earnings Estimates for Boardwalk Real Estate Investment Trust
Desjardins Analysts Increase Earnings Estimates for Boardwalk Real Estate Investment Trust
Raymond James Analysts Give Crescent Point Energy  a C$5.50 Price Target
Raymond James Analysts Give Crescent Point Energy a C$5.50 Price Target


© 2006-2019 Ticker Report